Related Experiment Video
Updated: May 21, 2026
Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
Published on: May 10, 2017
CD20 expression in B-cell precursor acute lymphoblastic leukemia is common in Mexican patients and lacks a prognostic
Manuel Solano-Genesta1, Luz Tarín-Arzaga, Ileana Velasco-Ruiz
1Servicio de Hematología, Hospital Universitario, 'Dr. José E. González' Universidad Autónoma de Nuevo León, Monterrey, Mexico.
Insights
CD20 expression is common in precursor B-cell acute lymphoblastic leukemia (ALL), particularly in Mexican patients. However, CD20 positivity does not appear to impact patient survival or relapse rates.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Flow cytometric immunophenotyping is crucial for classifying acute lymphoblastic leukemia (ALL).
- Understanding cell surface markers like CD20 aids in characterizing ALL and guiding therapy.
- CD20 expression varies across different ALL subtypes and populations.
Purpose of the Study:
- To investigate the prevalence of CD20 expression in newly diagnosed precursor B-cell ALL.
- To determine the correlation between CD20 expression and clinical/cytogenetic factors.
- To evaluate the prognostic significance of CD20 expression on patient outcomes.
Main Methods:
- Retrospective analysis of 143 patients with newly diagnosed precursor B-cell ALL.
- Flow cytometric immunophenotyping to assess CD20 expression at diagnosis.
- Statistical analysis to compare outcomes based on CD20 status.
Main Results:
- CD20 expression was detected in 61% of patients at diagnosis.
- No significant correlation was found between CD20 expression and age, WBC count, or cytogenetics.
- No significant differences in 3-year overall survival or cumulative incidence of relapse were observed between CD20-positive and CD20-negative groups in pediatric or adult patients.
- CD20 expression was more frequent in Mexican patients compared to Caucasian populations.
Conclusions:
- CD20 expression is a common finding in precursor B-cell ALL, especially in Mexican patients.
- CD20 expression in precursor B-cell ALL lacks prognostic value regarding survival and relapse.
- Further research may explore ethnic variations in CD20 expression in ALL.
Abstract:
Classification of acute lymphoblastic leukemia (ALL) by flow cytometric immunophenotyping characterizes the disease and delineates potential therapeutic intervention. We retrospectively analyzed CD20 expression in 143 patients with newly diagnosed precursor B-cell ALL. CD20 was observed in 61% of patients at diagnosis. There was no correlation between CD20 expression and age, white blood cell count, or cytogenetic abnormalities. Despite the fact that CD20-positive ALL patients had a tendency toward a worse outcome, there was no significant difference between patients with and without CD20 expression in 3-year overall survival 65 vs. 82% (P = 0.14), and cumulative incidence of relapse 36 vs. 18% (P = 0.3) in pediatric patients and 51 vs. 53% (P = 0.31) and 35 vs. 38% (P = 0.6) in adults, respectively. In conclusion, CD20 expression appears to be more common in Mexican patients with newly diagnosed precursor B-cell ALL higher than in Caucasian populations and lacks prognostic value.
